UNION HOSPITAL TONGJI MEDICAL COLLEGE HUST (20240352531). METHOD FOR DETECTING CD19 EXPRESSION simplified abstract
Contents
METHOD FOR DETECTING CD19 EXPRESSION
Organization Name
UNION HOSPITAL TONGJI MEDICAL COLLEGE HUST
Inventor(s)
Chenggong Li of Wuhan City (CN)
METHOD FOR DETECTING CD19 EXPRESSION - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240352531 titled 'METHOD FOR DETECTING CD19 EXPRESSION
The present invention relates to the efficacy monitoring of a chimeric antigen receptor (CAR)-T cell therapy in molecular biology.
- Use of a primer combination for detecting the prognostic effect of an anti-CD19 CAR-T cell therapy in a tumor.
- Use of a primer combination for detecting the expression state of CD19 on a tumor cell surface in a tumor patient.
- Product for detecting the prognostic effect of an anti-CD19 CAR-T cell therapy in a tumor, containing effective primers.
Potential Applications: - Monitoring the effectiveness of CAR-T cell therapy in treating tumors. - Personalized medicine for cancer patients based on CD19 expression levels. - Research in immunotherapy and cancer treatment.
Problems Solved: - Lack of efficient methods to monitor the efficacy of CAR-T cell therapy. - Difficulty in predicting the outcome of anti-CD19 CAR-T cell therapy. - Limited tools for assessing CD19 expression in tumor cells.
Benefits: - Improved prognosis prediction for patients undergoing CAR-T cell therapy. - Enhanced monitoring of treatment response in tumor patients. - Tailored treatment strategies based on individual CD19 expression levels.
Commercial Applications: Title: "Innovative Primer Combination for Efficacy Monitoring of CAR-T Cell Therapy" This technology can be utilized in clinical settings for better management of cancer patients undergoing CAR-T cell therapy. It has the potential to enhance treatment outcomes and patient care, leading to a more effective cancer treatment approach.
Questions about the technology: 1. How does the primer combination improve the monitoring of CAR-T cell therapy efficacy? 2. What are the implications of detecting CD19 expression levels in tumor cells for patient treatment outcomes?
Original Abstract Submitted
the present invention belongs to the technical field of molecular biology, and specifically relates to the technical field of efficacy monitoring of a chimeric antigen receptor (car)-t cell therapy. the present invention provides use of a primer combination in the preparation of a product for detecting a prognostic effect of an anti-cd19 car-t cell therapy in a tumor, where the primer combination includes primers shown in table 1. the present invention provides use of a primer combination in the preparation of a product for detecting an expression state of cd19 on a surface of a tumor cell in a tumor patient, where the primer combination includes primers shown in table 1. the present invention provides a product for detecting a prognostic effect of an anti-cd19 car-t cell therapy in a tumor, where the product includes primers shown in table 1 as effective components.
